Card image cap

After bempeg failure, Nektar wields the axe

Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in trials of its immuno-oncology candidate bempegaldesleukin, which was discontinued last week.

Card image cap

Editor (Deep Dive)

Manage the publication and production of Deep Dive magazine (content planning, commissioning, editing, interviewing, writing, managing advertisers and review process).